Supplemental Figure S1











Supplemental Fig. S1. A. Relative expression of ELL2 in cell lines 22Rv1, DU145, PC-3 and LNCaP as determined by western blot analysis. ELL2 band denoted by black arrow. **B**. Relative expression of ELL2 in cell lines C4-2, LNCaP, PC-3 and DU145 as determined by western blot analysis. GAPDH served as the loading control.

Supplemental Fig. S2. Identification of ELL2 alteration frequency in prostate cancer specimens from publicly available genomic datasets from the cBioPortal for Prostate Cancer Genomics. ELL2 alteration in prostate cancer (CaP), castration resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC). Data expressed as a percentage of total specimens, number of specimens in parentheses.

Supplemental Fig. S3. A. Western blot analysis of ELL2 and STAT1 in PC-3, C4-2 and LNCaP cells. ELL2 band denoted by black arrow. GAPDH was probed as the loading control.

Supplemental Fig. S4. Co-occurrence of genetic alterations in STAT1 and ELL2 in the neuroendocrine prostate cancer dataset from the cBioPortal for Prostate Cancer Genomics. Data are shown as an OncoPrint generated by the CBioPortal tool, each bar column represents an individual patient. Total patients with complete data for mutation, copy number alteration and mRNA expression in the dataset were 34.